Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biopharmaceutical pioneer leveraging computational discovery to advance novel cancer immunotherapies. This news hub provides investors and researchers with timely updates on clinical trials, strategic partnerships, and therapeutic innovations emerging from Compugen's AI-driven platform.
Access authoritative updates on key developments including COM701 (anti-PVRIG), COM902 (anti-TIGIT), and collaborative programs with industry leaders. Our curated news collection simplifies tracking of pipeline progress, peer-reviewed research publications, and milestone achievements in immuno-oncology.
Content spans clinical trial results, regulatory milestones, and partner collaboration updates, offering a comprehensive view of Compugen's position in next-generation cancer treatment development. Bookmark this page for streamlined access to verified information about therapeutic candidates and computational discovery breakthroughs.
Compugen Ltd. (CGEN) reported third-quarter 2021 results, highlighting the presentation of promising Phase 1/2 data for COM701, combined with Opdivo® and BMS-986207, at SITC. The studies indicated a favorable safety profile for the triple combination therapy, facilitating further evaluations in specific tumor types. The company also secured a $20 million equity investment from Bristol Myers Squibb and a $6 million milestone payment from AstraZeneca. Net loss for the quarter decreased to $6.2 million, while cash reserves totaled approximately $102 million, excluding recent financing.
Compugen Ltd. (CGEN) has announced preliminary results from its Phase 1/2 triple combination study of COM701, an anti-PVRIG antibody, with Opdivo and BMS-986207 targeting advanced solid tumors. The study, presented at the SITC 2021, showed no dose limiting toxicity and a favorable safety profile among 13 heavily pretreated patients. Encouraging outcomes include immune activation and stable disease in 3 patients. COM701 at 20 mg/kg is recommended for further study. Future enrollment in expansion cohorts is planned, highlighting the potential for addressing unmet medical needs in cancer therapy.
Compugen Ltd. (Nasdaq: CGEN) announced new translational data supporting the role of PVRIG as a differentiated checkpoint in cancer immunotherapy during the SITC 2021 conference. Preliminary findings indicate that PVRIG may enhance interactions between stem-like memory T cells and dendritic cells, potentially improving T cell proliferation and tumor infiltration compared to other checkpoints like TIGIT and PD-1. The presentation highlighted significant expressions of PVRIG and its ligand PVRL2, suggesting a promising therapeutic avenue for treating solid tumors.
Compugen Ltd. (CGEN) reported preliminary results from its Phase 1 dose escalation study of COM902, an anti-TIGIT antibody, for patients with advanced solid tumors, during the 36th Annual Meeting of the Society for Immunotherapy of Cancer. The study involved 18 heavily pretreated patients, achieving a 50% disease control rate. COM902 was well tolerated, with no maximum tolerated dose reached. The recommended dose for expansion is 3 mg/kg IV Q3W. Future studies will combine COM902 with COM701 to explore new therapeutic options.
Compugen Ltd. (Nasdaq: CGEN) announced a significant collaboration expansion with Bristol Myers Squibb (NYSE: BMY), which completed a $20 million investment in Compugen. This investment involved purchasing 2,332,815 shares at $8.57333 each, a 33% premium over the November 9, 2021 closing price. A new joint steering committee will oversee programs under the collaboration, aiming to advance clinical studies. Compugen's lead candidate, COM701, targets immune checkpoints in cancer therapy, showcasing its potential to enhance T cell activation in tumor environments.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy firm, announced its participation in several upcoming investor conferences. Notable events include the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 11:20 AM ET, and the Jefferies Virtual Healthcare Conference on November 18, 2021, with a recording available from 3:00 AM ET. Additional engagements include the Truist Securities SITC Breakfast on November 13, JMP Securities Virtual C-Suite on November 29, and the JMP Securities Virtual Hematology Oncology Summit on December 7. For more details, visit www.cgen.com.
Compugen Ltd. (NASDAQ: CGEN) will release its third quarter 2021 financial results on November 12, 2021, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide a corporate update. Additionally, Compugen will present data at the Society for Immunotherapy of Cancer Annual Meeting from November 10-14, 2021, with eposters available on the same day as the earnings release. Compugen focuses on cancer immunotherapy, with lead candidates COM701 and COM902 in Phase 1 studies.
Compugen Ltd. (NASDAQ: CGEN) announced a $6 million milestone payment from AstraZeneca (NASDAQ: AZN) following the first patient dosing in a Phase 1/2 study of AZD2936, a TIGIT/PD-1 bispecific antibody for lung cancer. This event marks the advancement of Compugen's COM902 program into clinical trials, contributing to its pipeline expansion. To date, Compugen has received a total of $12 million from AstraZeneca under their 2018 license agreement, which could potentially yield up to $200 million in milestone payments and royalties on sales.
Compugen Ltd. (NASDAQ: CGEN) announced the presentation of new clinical and preclinical data at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, scheduled for November 10-14, 2021. Key presentations include the evaluation of COM902, an anti-TIGIT antibody, in patients with advanced solid tumors, and the results of COM701 in combination with other therapies. Both studies emphasize safety, tolerability, and pharmacokinetics. Compugen continues to advance its lead product candidates in cancer immunotherapy, as they navigate through Phase 1 studies.
Compugen Ltd. (NASDAQ: CGEN) announced that it will present at the Cantor Global Healthcare Conference on September 30, 2021, at 1:20 pm ET. The presentation will cover its advancements in cancer immunotherapy, particularly focusing on COM701, an anti-PVRIG antibody, and COM902, targeting TIGIT. Both are in Phase 1 studies for treating solid and hematological tumors. A live webcast will be accessible via Compugen's website.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
